In January 1959, the pharmaceutical factory of Shandong Changwei Central Medicinal Materials Company was established.

In January 1964, the name of the factory was changed to "Weifang Wholesale Station Processing Factory of China Medicinal Materials Company".

In 1978,

lt;/stronggt; approved by Shandong Provincial Department of Health (78) Luwei Medicine No. 83, Xinkeshu Tablets were officially put into production. In January 1980, the name of the factory was changed to "Shandong Weifang Traditional Chinese Medicine Factory". In March, the "Shoushan" brand trademark was officially launched.

In March 1990, it passed the pharmaceutical factory production license renewal inspection organized by the Shandong Provincial Department of Health.

In January 1991

The name of the factory was restored from "Shandong Weifang Traditional Chinese Medicine Factory" to "Shandong Weifang Traditional Chinese Medicine Factory", and the affiliation remained unchanged.

In November, Amber Xiaoshi Granules won the silver medal at the "40th Eureka World Invention Expo".

In October 1992

The factory was renamed "Weifang Pharmaceutical Group Corporation Traditional Chinese Medicine Factory" and was under the leadership of Shandong Weifang Pharmaceutical Group Corporation.

1993

In May, Xinkeshu Tablets entered the basic catalog of clinical drugs in hospitals across the country.

In November, the name of the factory was changed to: "Shandong Weifang Pharmaceutical Group Co., Ltd. Traditional Chinese Medicine Factory", which is affiliated to Shandong Weifang Pharmaceutical Group.

In February 1994,

Xinkeshu Tablets, Amber Xiaoshi Granules, and Pediatric Antipyretic Granules were included in the national second-level protected varieties of traditional Chinese medicine, with a protection period of 7 years.

In March, Xinkeshu Tablets were included in Shanghai’s public medical directory.

In July, it passed the acceptance of the health license and drug production license organized by the Shandong Provincial Department of Health.

In February 1996,

Xinkeshu Tablets were recommended by the State Administration of Traditional Chinese Medicine as a "Chinese famous brand product of traditional Chinese medicine".

In March 1997, the development of Xinkeshu film-coated tablets won the "Second Prize for Scientific and Technological Progress Award from the Shandong Provincial Medical Administration Administration".

In May, Xinkeshu Tablets were included in Beijing’s public medical catalog.

At the end of August, the Xinkeshu workshop expansion and transformation project was completed and passed acceptance inspection.

In November, Xinkeshu film-coated tablets were included in the national key support new product catalog and obtained the national key new product certificate.

1998

lt;/stronggt;In April, Xinkeshu film-coated tablets won the honors of the National Science and Technology Commission, the State Taxation Bureau, the Ministry of Foreign Trade and Economic Cooperation, and the State Administration of Technical Supervision. , the National Key New Product Certificate jointly issued by six ministries and commissions of the National Environmental Protection Administration.

In October, with the approval of the Weizhengban Fuzi [1998] No. 120 document of the Weifang Municipal People's Government Office, it was designated as a medium (I) enterprise. In February 2000, the in vitro diagnostic reagent workshop passed the GMP certification organized by the State Food and Drug Administration.

In May, the company's exclusive traditional Chinese medicine protected variety Xinkeshu Tablets was included in the "National Basic Medical Insurance and Work Injury Insurance Drug Catalog".

In July, the State Food and Drug Administration announced the first batch of over-the-counter drug catalogs, with 34 varieties and 36 specifications of products selected.

In January 2001, the declared Xinskeshu Capsule obtained the national second-class protected variety of traditional Chinese medicine, with a protection period of 7 years.

In February, 34 varieties and 35 specifications of non-prescription drugs declared passed the review of the Provincial Food and Drug Administration and received certificates.

In the same month, Xinkeshu Tablets, Amber Xiaoshi Granules, and Xiaoer Tuifeng Granules were granted Phase II national traditional Chinese medicine protection, with a protection period of 7 years.

In the same month, the "Helicobacter pylori urease diagnostic kit project" was listed as a National Torch Plan project by the Ministry of Science and Technology.

In April, the solid preparation workshop successfully passed the on-site acceptance of GMP certification organized by the State Food and Drug Administration.

In the same month, Orange Pear Paste obtained the second-level protection of the national protected variety of traditional Chinese medicine, with a protection period of 7 years.

2002

lt;/stronggt; In February, the signing ceremony of the property rights transfer contract between Shandong Weifang Pharmaceutical Group Co., Ltd. and Beijing Wohua Biotechnology Co., Ltd. was held at Weifang Fuhua University Held at the hotel. Zhang Xinqi, deputy secretary of the Weifang Municipal Party Committee and executive deputy mayor, attended the signing ceremony and delivered a speech. Zhao Bingxian, Zhao Jun, and Zhang Fazhong signed the contract on behalf of Beijing Wohua Biotech, Weifang Pharmaceutical Group and the company's senior executives respectively.

In February, the first meeting of the first board of directors of Weifang Wohua Pharmaceutical was held in Weifang. Zhao Bingxian was elected as chairman, Zhao Jun was appointed as president of the company, Zhang Fazhong was appointed as executive vice president, and Zhang Ge was appointed chief financial officer. , Huang Gang is the secretary of the board of directors.

In February, with the approval of the Weifang Industrial and Commercial Bureau High-tech Industrial Development Zone Branch, Weifang Wohua Pharmaceutical Technology Co., Ltd. was registered and established in 2002 and issued a business license. The company’s legal representative Zhao Bingxian and the person in charge Zhao Jun , with a registered capital of 16.35 million yuan.

In August, the Shoushan Xinkeshu Research Center of Weifang Wohua Pharmaceutical Technology Co., Ltd. was registered and established.

In November, the Weifang Municipal Economic and Trade Commission and the Bureau of Statistics reviewed and approved the company as a medium (II) enterprise.

In March 2003, Shandong Wohua Pharmaceutical Technology Co., Ltd. was established.

In the same month, the antiviral oral liquid was listed as a national second-level protected variety of traditional Chinese medicine, with a protection period of 7 years.

In April, the "Development of Xinskeshu Dropping Pills" project applied by the company was included in the national "863 Plan" and received the innovation fund for the project.

In December, 9 dosage forms in the company’s third workshop that underwent GMP transformation passed the certification at one time. So far, all the company's production dosage forms have passed GMP certification.

In the same month, production management, warehousing management and financial management officially used Kingdee software to realize office modernization. In January 2004, the company implemented an additional issuance plan. With the approval of the Shandong Provincial People's Government, the company's registered capital increased from 39.99 million yuan to 51.99 million yuan.

In April, the company applied for the "Xinkeshu Dropping Pills Transformation Project", "Xinkeshu Tablets Transformation Project", "Chinese Medicine Pieces and Granules Transformation Project", and "Biological Diagnostic Reagent Transformation Project" It was included in Shandong Province's 2004 technological transformation-oriented plan, with a total planned investment of 170 million yuan.

In May, the company established a stock issuance and listing leading group, a price, medical insurance, bidding, quality and government relations leading group and an internal risk prevention and emergency leading group.

In the same month, the company was recognized as a "National Torch Plan Key High-tech Enterprise" by the Ministry of Science and Technology.

In June, the Xinkeshu Dropping Pills project was listed as a "Technological Innovation Project for Small and Medium-Sized Enterprises" by the Ministry of Science and Technology, and the "Research on Key Technologies for Innovative Drugs and Modernization of Traditional Chinese Medicine" organized by the Department of Science and Technology of Shandong Province Winning the bid in the public tender.

In August, after acceptance by the Shandong Provincial Securities Regulatory Bureau, the company successfully passed the listing guidance acceptance and was highly praised.

In the same month, the newly added dripping pill dosage form workshop passed the on-site additional inspection and acceptance by the provincial drug regulatory department.

In September, Amber Xiaoshi Granules and Motherwort Oral Liquid were included in the newly adjusted "National Basic Medical Insurance and Work Injury Insurance Drug Catalog". In April 2005, the company successfully passed Received the listing guidance and acceptance organized by the Shandong Provincial Securities Regulatory Bureau.

In the same month, our company’s Motherwort Oral Liquid obtained the National Traditional Chinese Medicine Protection Certificate and was listed as a national second-level protected traditional Chinese medicine variety with a protection period of 7 years.

In July, the CIS system designed by the company entrusted by Beijing Zhengbang Advertising Company officially entered the introduction stage, and Wohua's new logo and the slogan "Good medicine is good for people, good medicine is good for people" were officially launched. The new logo is composed of blue It is composed of and green, and the whole is a deformation of the word "Wo", which has a profound meaning;

In September, the company's in vitro diagnostic reagent workshop successfully passed the GMP re-certification.

In November, the 150-acre land quota for the company’s new factory in the development zone was approved, and the new area plan passed the approval of the development zone planning department.

In January 2006, the solid preparation workshop successfully passed the on-site acceptance of the secondary GMP certification organized by the State Food and Drug Administration.

In April, the company's "High-tech Industrial Development Zone Construction Project passed the process design demonstration by the Shandong Provincial Food and Drug Administration, the High-tech Zone, and the Weifang Fire Department.

In May, the company The groundbreaking ceremony for the new factory construction project was held in the High-tech Development Zone.

In June, the "Weifang High-tech Industry Development Special Fund Shandong Wohua Traditional Chinese Medicine Research Institute Construction Project" passed the review of the Weifang Municipal Government.

In the same month, the company registered the Wohua trademark and gradually quoted it on product packaging.

In September, Xinkeshu Tablets passed the "High Quality and Good Price of Chinese Patent Medicines" organized by the China Association of Traditional Chinese Medicine. Expert review.

On December 18, the 78th meeting of the Review Committee of the State Securities Regulatory Commission reviewed and approved the company’s application for issuance of A shares on the Shenzhen Stock Exchange.

In 2007.

On January 14, the company issued 18 million tradable shares on the Shenzhen Stock Exchange, with an issue price of 10.85 yuan/share.

On January 24, the company’s shares were listed on the Shenzhen Stock Exchange. The enterprise board was officially listed on the stock market with the stock code of 002107. The success of the stock listing has consolidated and developed the company's core competitive advantages and enhanced the company's development potential. The company has since entered a period of rapid development.

In January, The company's new drug variety Xinkeshu Dropping Pills passed the invention patent approval of the State Intellectual Property Office and became the company's first variety with a national patent. The patent period is 20 years.

In February, the National Development and Reform Commission issued the "National Development and Reform Commission". According to the Notice of the National Development and Reform Commission on Setting the Maximum Retail Price of 278 Kinds of Chinese Patent Medicines for Internal Medicine, the company's product Xinkeshu Tablets (specification: 0.3g, 48 tablets, film-coated) will implement high-quality and preferential prices from March 15, and its maximum retail price will be from 19.8 Yuan/box was adjusted to 24.2 Yuan/box.

In April, the company's "Development and Research on the National Five New Chinese Medicines Xinkeshu Dropping Pills" undertaken by the National Science and Technology Small and Medium-sized Enterprises Technology Innovation Fund project was passed. Acceptance by the Shandong Provincial Department of Science and Technology.

In September, the company’s leading product Xinkeshu Tablets “A Preparation of Xinkeshu Tablets” was granted a patent certificate by the National Patent Office, with a patent period of twenty years

In November, the company was once again recognized as a national high-tech enterprise.

In December, the company’s new drug Naoxueshu Oral Liquid passed the approval and obtained the production approval document and new drug certificate issued by SFDA. The approval number is: National Pharmaceutical Approval No. Z20070059.

In December, the company’s vice chairman Zhao Jun was elected as a representative of the 15th Weifang Municipal People’s Congress and a candidate for the Weifang Municipal People’s Congress Standing Committee.